<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113165</article-id><article-id pub-id-type="publisher-id">ACM-41051</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_93576803.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  饥饿素在糖代谢中的作用以及在糖尿病中的研究综述
  Review on the Role of Ghrelin in Glucose Metabolism and Diabetes Mellitus
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>晶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>冬静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>颜刚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>山东省单县中心医院内分泌科，山东 菏泽</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1147</fpage><lpage>1153</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    饥饿素(Ghrelin)是1999年发现的一种28氨基酸(AA)胃源性肽，是生长激素促分泌受体(GHSR)的内源性配体。能够分泌Ghrelin的细胞构成一组组功能独特的内分泌细胞群，主要分布于胃粘膜，在小肠和内分泌胰腺中较少。空腹和热量限制摄入(如少食)期间，血浆Ghrelin水平升高，以刺激食物摄入和脂肪储存，防止的血糖进一步下降，进而危及生命。餐后及能量过剩(如肥胖)时，血浆Ghrelin水平降低，其血糖调节功能不明显。最新研究表明，Ghrelin已成为调节食欲和能量平衡的关键因子，Ghrelin通过在食欲调节神经元和包括内分泌胰腺在内的外周代谢器官中结合Ghrelin受体GHSR来实现这些功能。Ghrelin水平与体重指数(BMI)和胰岛素抵抗呈负相关。一些研究强调Ghrelin在葡萄糖稳态中的重要作用。基因、免疫和药物阻断Ghrelin信号导致糖耐量和胰岛素敏感性的改善。此外，外源性Ghrelin给药可降低葡萄糖诱导的胰岛素释放，提高人和实验动物血浆的葡萄糖水平。GHSR可以在胰腺β细胞中稳定表达，Ghrelin通过Ca
   <sup>2+</sup>通道抑制胰岛素释放。Ghrelin对糖代谢和脂质稳态的影响可能为治疗肥胖相关的2型糖尿病和相关代谢功能障碍新的靶点，进而提供新的预防或早期干预治疗策略。本综述着眼于探究Ghrelin在机体糖代谢的作用，以及与糖尿病的相关性，从而明确Ghrelin在糖尿病中的作用，进而为糖尿病的治疗提供新的思路和方法。
    Ghrelin is a 28 amino acid (AA) gastrointestinal peptide discovered in 1999. It is an endogenous ligand of growth hormone secretagogue receptor (GHSR). Cells which can secrete ghrelin to constitute a group of endocrine cells with unique functions, mainly distributed in the gastric mucosa, but less in the small intestine and endocrine pancreas. During fasting and caloric restriction (such as eating less), the levels of plasma ghrelin l are elevated to stimulate food intake and fat storage, preventing a further drop in blood sugar that can be life-threatening. Plasma ghrelin levels are reduced after meal and in excess energy (e.g., obesity), and its glycemic regulation function is not obvious. Recent studies have shown that ghrelin has become a key factor in regulating appetite and energy balance. It can achieve those functions by binding itself to the GHSR receptor both in appetite regulating neurons and in peripheral metabolic organs, including the endocrine pancreas. Ghrelin levels were negatively correlated with body mass index (BMI) and insulin resistance. Some studies have highlighted the important role of ghrelin in glucose homeostasis. Gene, immune and drug blocking ghrelin signal led to improved glucose tolerance and insulin sensitivity. In addition, the administration of exogenous ghrelin can reduce glucose-induced insulin release and increase the plasma glucose level of human beings and experimental animals. GHSR is stably expressed in beta cells of the pancreas, and ghrelin inhibits insulin release through Ca
   <sup>2+</sup> channels. The effect of ghrelin on glucose metabolism and lipid homeostasis may be a new target for the treatment of obesity-related type 2 diabetes and related metabolic dysfunction, thus providing new prevention or early intervention strategies. This review aims to explore the role of ghrelin in the body’s glucose metabolism and its correlation with diabetes, so as to clarify the role of ghrelin in diabetes, and thus provide new ideas and methods for the treatment of diabetes. 
  
 
</p></abstract><kwd-group><kwd>饥饿素，糖尿病，糖尿病肾病，胰岛素, Ghrelin</kwd><kwd> Diabetes</kwd><kwd> Diabetic Nephropathy</kwd><kwd> Insulin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>饥饿素(Ghrelin)是1999年发现的一种28氨基酸(AA)胃源性肽，是生长激素促分泌受体(GHSR)的内源性配体。能够分泌Ghrelin的细胞构成一组组功能独特的内分泌细胞群，主要分布于胃粘膜，在小肠和内分泌胰腺中较少。空腹和热量限制摄入(如少食)期间，血浆Ghrelin水平升高，以刺激食物摄入和脂肪储存，防止的血糖进一步下降，进而危及生命。餐后及能量过剩(如肥胖)时，血浆Ghrelin水平降低，其血糖调节功能不明显。最新研究表明，Ghrelin已成为调节食欲和能量平衡的关键因子，Ghrelin通过在食欲调节神经元和包括内分泌胰腺在内的外周代谢器官中结合Ghrelin受体GHSR来实现这些功能。Ghrelin水平与体重指数(BMI)和胰岛素抵抗呈负相关。一些研究强调Ghrelin在葡萄糖稳态中的重要作用。基因、免疫和药物阻断Ghrelin信号导致糖耐量和胰岛素敏感性的改善。此外，外源性Ghrelin给药可降低葡萄糖诱导的胰岛素释放，提高人和实验动物血浆的葡萄糖水平。GHSR可以在胰腺β细胞中稳定表达，Ghrelin通过Ca<sup>2+</sup>通道抑制胰岛素释放。Ghrelin对糖代谢和脂质稳态的影响可能为治疗肥胖相关的2型糖尿病和相关代谢功能障碍新的靶点，进而提供新的预防或早期干预治疗策略。本综述着眼于探究Ghrelin在机体糖代谢的作用，以及与糖尿病的相关性，从而明确Ghrelin在糖尿病中的作用，进而为糖尿病的治疗提供新的思路和方法。</p></sec><sec id="s2"><title>关键词</title><p>饥饿素，糖尿病，糖尿病肾病，胰岛素</p></sec><sec id="s3"><title>Review on the Role of Ghrelin in Glucose Metabolism and Diabetes Mellitus</title><p>Jing Chen, Dongjing Zhao, Yangang Wang</p><p>Department of Endocrinology, Shanxian Central Hospital, Heze Shandong</p><p><img src="//html.hanspub.org/file/48-1571725x4_hanspub.png" /></p><p>Received: Feb. 17<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/48-1571725x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Ghrelin is a 28 amino acid (AA) gastrointestinal peptide discovered in 1999. It is an endogenous ligand of growth hormone secretagogue receptor (GHSR). Cells which can secrete ghrelin to constitute a group of endocrine cells with unique functions, mainly distributed in the gastric mucosa, but less in the small intestine and endocrine pancreas. During fasting and caloric restriction (such as eating less), the levels of plasma ghrelin l are elevated to stimulate food intake and fat storage, preventing a further drop in blood sugar that can be life-threatening. Plasma ghrelin levels are reduced after meal and in excess energy (e.g., obesity), and its glycemic regulation function is not obvious. Recent studies have shown that ghrelin has become a key factor in regulating appetite and energy balance. It can achieve those functions by binding itself to the GHSR receptor both in appetite regulating neurons and in peripheral metabolic organs, including the endocrine pancreas. Ghrelin levels were negatively correlated with body mass index (BMI) and insulin resistance. Some studies have highlighted the important role of ghrelin in glucose homeostasis. Gene, immune and drug blocking ghrelin signal led to improved glucose tolerance and insulin sensitivity. In addition, the administration of exogenous ghrelin can reduce glucose-induced insulin release and increase the plasma glucose level of human beings and experimental animals. GHSR is stably expressed in beta cells of the pancreas, and ghrelin inhibits insulin release through Ca<sup>2+</sup> channels. The effect of ghrelin on glucose metabolism and lipid homeostasis may be a new target for the treatment of obesity-related type 2 diabetes and related metabolic dysfunction, thus providing new prevention or early intervention strategies. This review aims to explore the role of ghrelin in the body’s glucose metabolism and its correlation with diabetes, so as to clarify the role of ghrelin in diabetes, and thus provide new ideas and methods for the treatment of diabetes.</p><p>Keywords:Ghrelin, Diabetes, Diabetic Nephropathy, Insulin</p><disp-formula id="hanspub.41051-formula16"><graphic xlink:href="//html.hanspub.org/file/48-1571725x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/48-1571725x7_hanspub.png" /> <img src="//html.hanspub.org/file/48-1571725x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>既往研究均证明，饥饿素(Ghrelin)具有促食欲作用，内源性Ghrelin系统对食物摄取、食物报酬、体重、肥胖和能量消耗均由一定程度的影响。尽管内源性Ghrelin在其中一些过程中的作用仍不明确。在类似饥饿的情况下，Ghrelin的血糖升高作用是有益的，可以防止血糖下降危及生命，但在肥胖状态和某些单基因型糖尿病中，Ghrelin可以促进的血糖升高，进而导致糖尿病的发生。同样值得注意的是，血糖对Ghrelin的分泌有负调节作用。本文回顾了一些文献，认为存在血糖-Ghrelin轴，并强调了调节Ghrelin葡萄糖调节作用的因素，特别是在代谢极端如饥饿状态和糖尿病状态下的调节作用。</p></sec><sec id="s6"><title>2. 饥饿素(Ghrelin)</title><p>1996年，在猪和人垂体cDNA文库中克隆了GHSR受体，3年后，在大鼠胃中发现了内源性GHSR激动剂Ghrelin，随后证实，外周循环血中的Ghrelin主要来源于胃壁 [<xref ref-type="bibr" rid="hanspub.41051-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41051-ref2">2</xref>]，但是在胎儿期的时候，Ghrelin主要在胰岛中分泌产生。在成年小鼠中很难找到产生Ghrelin的胰岛细胞，而在人类中，它们只占内分泌胰岛细胞类型的1% [<xref ref-type="bibr" rid="hanspub.41051-ref3">3</xref>]。Ghrelin的酰化形式通过结合和激活GHSRs而发挥作用，GHSRs可以在选定的神经元群中表达，如内源性弓状下丘脑刺鼠相关肽(AgRP)/神经肽Y神经元，以及一些外周组织，如胃肠道和胰岛组织 [<xref ref-type="bibr" rid="hanspub.41051-ref4">4</xref>]。GHSRs可以与Ghrelin高度结合，在体外实验检测时，GHSRs与Ghrelin结合后，可以进一步刺激细胞内第二信使信号级联系统，进而发挥作用 [<xref ref-type="bibr" rid="hanspub.41051-ref5">5</xref>]。除Ghrelin和GHSR外，Ghrelin系统的其他重要元素还包括Ghrelin O-酰基转移酶(也称为膜结合O-酰基转移酶4) (它的作用是负责催化Ghrelin蛋白的酰化)和富含肝脏的抗菌肽2 (LEAP2)，后者最近被认为是GHSR (31)的内源性拮抗剂 [<xref ref-type="bibr" rid="hanspub.41051-ref6">6</xref>]。同样值得注意的是，外周血循环池中的Ghrelin蛋白是以非环化形式分泌的，也可以通过包括丁酰胆碱酯酶和酰基蛋白硫酯酶1在内的酶的作用使循环中的Ghrelin蛋白前体快速酰基化而快速脱环，进而得到Ghrelin的前体 [<xref ref-type="bibr" rid="hanspub.41051-ref7">7</xref>]。虽然目前的研究表明，Ghrelin的致食欲作用和内源性Ghrelin系统对食物摄入、食物报酬、体重、肥胖和能量消耗的密切相关，但是Ghrelin系统与血糖代谢的关系也越来越引起广大学者的兴趣。</p></sec><sec id="s7"><title>3. 饥饿素(Ghrelin)与血糖的调节</title><p>有研究表明，在给实验对象静脉滴注Ghrelin时，会使机体的血糖水平急剧升高，但是具体的机制和原因不详。在动物实验的研究表明，给动物体内注射Ghrelin时，动物的血糖水平也会相应增高，但是无论是人体试验还是动物实验，静脉滴注Ghrelin时，可以造成机体或者实验动物的糖耐量异常。所以，他们认为，外周循环血中的Ghrelin含量过高时，可以导致糖耐量的异常 [<xref ref-type="bibr" rid="hanspub.41051-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41051-ref9">9</xref>]。并且，静脉注射GHSR或Ghrelin拮抗剂可降低小鼠的空腹血糖并改善其葡萄糖耐量。也有研究表明，在平常情况下，缺乏Ghrelin功能的基因缺陷小鼠模型(包括Ghrelin敲除(KO)、GOAT敲除(KO)、GHSR敲除KO和GHSR基因沉默小鼠)表现出与野生型小鼠相似的血糖水平，但当受到外周血中葡萄糖含量急剧增高的挑战时，它们就会表现出明显的糖耐量的异常 [<xref ref-type="bibr" rid="hanspub.41051-ref10">10</xref>]。也有研究表明，在高脂饮食喂养的小鼠模型中，葡萄糖耐量的改善并没有伴随着体重的增加而发生变化。因此，他们认为，尽管在饮食诱导肥胖的小鼠模型中，外周血中Ghrelin普遍较低，但外周血中Ghrelin的较低量足以导致葡萄糖耐量的异常 [<xref ref-type="bibr" rid="hanspub.41051-ref11">11</xref>]。有的研究表明，静脉注射Ghrelin 2小时后会增加体重正常对照者和肥胖者的血糖水平，与体重正常的对照人群相比，肥胖者的血糖升高幅度更高 [<xref ref-type="bibr" rid="hanspub.41051-ref12">12</xref>]。</p><p>在一些减肥实验中，Ghrelin的糖调节作用也被研究过。例如，缺乏Ghrelin功能的小鼠模型在一夜禁食后表现出较低的血糖水平。如果实验动物出现极致饥饿的情况下，可能出现致命性的低血糖水平 [<xref ref-type="bibr" rid="hanspub.41051-ref13">13</xref>]。在以接受Roux-en-Y胃转流术(RYGB)肥胖的人群受试者为研究对象，术后2周检测血清中的Ghrelin水平和血糖水平，结果表明，Ghrelin静脉输注在增加血糖方面无效 [<xref ref-type="bibr" rid="hanspub.41051-ref14">14</xref>]。在动物实验中，接收垂直套筒下小鼠胃切除术后，野生型小鼠血浆内的Ghrelin水平明显下降，葡萄糖耐量可以明显改善 [<xref ref-type="bibr" rid="hanspub.41051-ref15">15</xref>]。但是，也有相反的研究表明，在接收垂直套筒下小鼠胃切除术后，小鼠血清中Ghrelin的减少并不能改善葡萄糖耐量 [<xref ref-type="bibr" rid="hanspub.41051-ref16">16</xref>]。所以，相反的结果说明，血清中Ghrelin的水平对血糖的相关升高作用高度依赖于个体的营养和代谢状态。</p><p>Ghrelin对血糖的调控作用是可以通过下游效应器参与的过程，这些过程包括胰岛素敏感性的降低。此外，这些还包括对几个主要胰岛内分泌细胞类型的直接或间接影响，例如，抑制胰岛β细胞的胰岛素分泌。其他因素包括胰腺α细胞胰高血糖素分泌的调节和胰腺β细胞生长抑素(Somatostatin简称SST)分泌的刺激、肠L细胞胰高血糖素样肽-1 (GLP-1)分泌和垂体生长激素GHSE分泌。食物摄入刺激也可能很重要，糖皮质激素在Ghrelin相关的血糖调节中的作用尚不明确 [<xref ref-type="bibr" rid="hanspub.41051-ref17">17</xref>]。尽管还需要进一步的研究来确定这些因子在调节Ghrelin的糖调节作用方面的作用，但看起来很明显的是，Ghrelin对这些因子的补充依赖于个体的营养和代谢状态。</p><sec id="s7_1"><title>3.1. 饥饿素(Ghrelin)与胰岛素分泌与胰岛素敏感性</title><p>胰岛素分泌减少和/或胰岛素敏感性形成一个主要的刺激因素，Ghrelin通过该刺激因素在餐后环境和肥胖条件下升高血糖。静脉滴注Ghrelin蛋白对胰岛素的刺激作用并不明确，有的研究认为，静脉滴注Ghrelin蛋白可以抑制胰岛素的释放，有的研究认为静脉滴注Ghrelin蛋白可以促进胰岛素的释放，也有的研究认为静脉滴注Ghrelin蛋白与胰岛素的释放是没有关系的。而动物实验中，以小鼠作为研究对象，肌肉注射或静脉注射Ghrelin剂量依赖性地抑制葡萄糖刺激的胰岛素分泌 [<xref ref-type="bibr" rid="hanspub.41051-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41051-ref19">19</xref>]。相反，抑制Ghrelin的活性可以增强葡萄糖刺激的胰岛素分泌，改善了小鼠的葡萄糖耐量。在GHSR-null和Ghrelin-KO小鼠中观察到的葡萄糖耐量的改善也伴随着葡萄糖刺激的胰岛素分泌的增强，并且与胰岛的密度、大小、胰岛素蛋白含量或胰岛素mRNA水平的改变无关。在高脂饮食中Ghrelin-KO和GOAT-KO小鼠的葡萄糖耐受与胰岛素反应增强相关。相反地，如果小鼠体内的Ghrelin基因过度表达后，会导致转基因小鼠在受到葡萄糖刺激时，胰岛素的分泌减少 [<xref ref-type="bibr" rid="hanspub.41051-ref20">20</xref>]。外源性注射Ghrelin也可以抑制人类受试者餐后胰岛素分泌和葡萄糖刺激的胰岛素分泌 [<xref ref-type="bibr" rid="hanspub.41051-ref21">21</xref>]。令人遗憾的是，关于内源性Ghrelin对胰岛素分泌的作用尚未见报道。</p><p>Ghrelin抑制胰岛素分泌的机制很可能是对胰岛组织产生的直接作用。有研究表明，将实验小鼠的Ghrelin表达抑制后，胰腺中胰岛组织分泌胰岛素的含量增加，而药物阻断GHSR后，可以促进胰岛素的释放，他们的结果均证明，Ghrelin可以直接作用于胰岛细胞，进而抑制胰岛组织分泌胰岛素。但是，比较有趣的结果显示，Ghrelin对胰岛素分泌的抑制作用在GHSR缺失小鼠中不存在，这表明Ghrelin的这种作用依赖于GHSR的表达 [<xref ref-type="bibr" rid="hanspub.41051-ref5">5</xref>]。类似的研究表明，Ghrelin对胰岛素分泌的抑制作用可以通过对胰腺β细胞表达的GHSRs直接参与。例如，Ghrelin蛋白可以与GHSR相结合，进一步减弱细胞内钙离子浓度，从而抑制单个胰岛β细胞动作电位的激活，从而抑制胰岛组织分泌胰岛素。进一步探究其机制，证明Ghrelin蛋白与GHSR相结合后，可以对钙离子通道发生改变，进而抑制胰岛β细胞动作电位的激发。还与百日咳毒素敏感的G蛋白信号通路，瞬时受体电位2 (TRPM2)通路和电压依赖性KV钾电流的改变有关 [<xref ref-type="bibr" rid="hanspub.41051-ref22">22</xref>]。此外，有研究表明，在胰腺β细胞中可以选择性表达GHSR，并且可以通过将具有大鼠胰岛素启动子的Cre重组酶的转基因小鼠与具有Cre依赖性GHSR表达的小鼠杂交，进而恢复内源性Ghrelin的胰岛素抑制作用。GHSR在一些胰岛素瘤细胞系INS-1SJ、INS-1 (832/13)、INS-1E、bTC6和MIN6中也有表达。此外，Ghrelin还可以抑制胰腺β细胞在葡萄糖的刺激下对胰岛素的过多释放 [<xref ref-type="bibr" rid="hanspub.41051-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.41051-ref24">24</xref>]。</p></sec><sec id="s7_2"><title>3.2. 饥饿素(Ghrelin)与胰高血糖素的作用</title><p>长期注射外源性Ghrelin蛋白或通过Ghrelinomas转基因过度表达后导致的小鼠血浆Ghrelin升高，会进一步导致小鼠血浆内胰高血糖素升高，而与此相反，GHSR阴性小鼠的空腹血浆胰高血糖素降低，从而降低血糖水平。这些结果与Ghrelin诱导小鼠胰岛和胰腺α细胞株aTC1和InR1G9分泌胰高血糖素的结果相结合，提示Ghrelin可以直接刺激胰腺α细胞分泌胰高血糖素，从而提高血浆中血糖含量 [<xref ref-type="bibr" rid="hanspub.41051-ref25">25</xref>]。然而，上述两项胰岛转录组研究中只有一项研究证明，在分离的α细胞中可以表达GHSR mRNA，并且其水平相当低。同样，使用灌流小鼠胰腺模型，同样的研究表明Ghrelin可以以SST依赖的方式减少胰高血糖素释放，再次表明GHSR是Ghrelin与胰高血糖素必不可少的部分 [<xref ref-type="bibr" rid="hanspub.41051-ref26">26</xref>]。Ghrelin对胰高血糖素释放的间接影响也可能通过下丘脑弓状核发生。尤其是，弓状AgRP/神经肽Y神经元限制性GHSR表达的禁食小鼠的血浆胰高血糖素和血糖水平与禁食野生型小鼠相似，而禁食GHSR空白小鼠的血浆胰高血糖素和血糖水平较低。然而，血浆胰高血糖素在随意喂养的GAOT-KO小鼠中是不变的。因此，Ghrelin利用胰高血糖素作为提高血糖途径的潜力似乎仅限于设置一夜禁食，而不发生在非禁食条件下。需要进一步的研究来确定胰高血糖素在这些条件下介导Ghrelin的糖调节作用。</p></sec></sec><sec id="s8"><title>4. Ghrelin与糖尿病的相关性研究</title><p>Ghrelin可能影响糖尿病(DM)患者的血糖水平，并且肥胖者和2型糖尿病(T2DM)患者血浆Ghrelin水平较低。有研究以肥胖小鼠模型为研究对象，通过饮食诱导后，他们发现实验动物血清中的Ghrelin含量较低，然而，尽管血浆Ghrelin水平较低，但GHSR的慢性药物阻断或Ghrelin基因敲除后，仍旧可以改善饮食诱导肥胖小鼠的葡萄糖耐量。而瘦素缺乏(ob/ob)小鼠是一般都是体重偏重，多伴有糖尿病，当ob/ob小鼠与Ghrelin-KO杂交后，检测发现杂交小鼠具有血糖降低，血浆胰岛素降低，葡萄糖耐量增加的特点，这些结果表明Ghrelin对ob/ob小鼠模型糖尿病的治疗具有积极意义，但是对小鼠的体重影响不大 [<xref ref-type="bibr" rid="hanspub.41051-ref27">27</xref>]。另外，连续6天给ob/ob小鼠模型注射GHSR拮抗剂也能降低血糖。同样，长期服用GHSR的反向激动剂也能改善糖尿病超重大鼠模型的葡萄糖耐量。也有研究者提出相反的观点，他们的研究表明在ob/ob小鼠中沉默Ghrelin基因的表达并不改变ob/ob小鼠的葡萄糖耐量，敲除ob/ob小鼠的GHSR会导致高血糖和葡萄糖耐量的恶化。不同的研究结果可能与GHSR高构形活性有关，或者Ghrelin的作用与其单环状态密切相关。总之，Ghrelin与糖尿病密切相关，但是与体重控制无关。因此，阻断Ghrelin系统作为改善肥胖/T2DM患者糖耐量的方法 [<xref ref-type="bibr" rid="hanspub.41051-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.41051-ref29">29</xref>]。</p><p>虽然1型糖尿病(T1DM)患者血浆Ghrelin的变化没有一致的报道，但在动物实验中，用链脲佐菌素处理胰β细胞后，可以造成血浆中Ghrelin和总Ghrelin升高。值得注意的是，基因沉默GHSR后也能降低链脲佐菌素诱导的小鼠的空腹血糖异常情况。这些结果表明，外周循环学中的Ghrelin升高可导致T1DM患者血糖升高。但是具体的机制需要进一步的研究 [<xref ref-type="bibr" rid="hanspub.41051-ref30">30</xref>]。</p><p>还有研究证明，除了T1DM和T2DM的患者之外，患有肝细胞核因子-1a-相关的糖尿病和葡萄糖激酶-MODY (或MODY2)型糖尿病的人血浆Ghrelin也升高。MODY3小鼠模型中外周血Ghrelin和总Ghrelin水平也明显升高，这可能与HNF-1a缺乏相关。用GHSR拮抗剂同样可以降低小鼠模型外周血中的高血糖水平，从而改善低胰岛素血症，进一步影响葡萄糖耐量。因此，Ghrelin的增加可能有助于MODY3型糖尿病患者胰岛素分泌受损和血糖水平异常，但是血浆Ghrelin升高的原因尚不明确 [<xref ref-type="bibr" rid="hanspub.41051-ref31">31</xref>]。</p></sec><sec id="s9"><title>5. 以Ghrelin系统为靶点可以控制血糖水平</title><p>Ghrelin蛋白在糖尿病中的相关作用引起了人们对研制Ghrelin拮抗剂和相关化合物的研究兴趣，对糖尿病患者的胰岛素抵抗情况和葡萄糖不耐受情况进行探索，为糖尿病患者的治疗提供新的思路和方法。使用GHSR或Ghrelin拮抗剂代替现有的抗糖尿病药物的好处是，它们有可能改善葡萄糖稳态，而不会导致显著的低血糖，根据动物实验的研究结果，这种情况可能只发生在特定的环境中，比如饥饿状态。尽管这些药物在临床前研究中是有效的，而且至少有一种药物已经进入了第一阶段的临床试验，但还没有一种药物成功上市。最新的研究表明，LEAP2可以作为内源性GHSR拮抗剂，其作用靶点是靶向调控GHSR的构象关系。研究表明，在负能量平衡的情况下，小鼠过表达LEAP2基因可以降低动物模型的外周血的血糖水平。至于提高LEAP2活性的方法是否能改善糖尿病患者的血糖稳态，还有待于检验。在一项随机安慰剂对照临床试验中，该化合物也被证明能改善患有Prader-Willi综合征的成年受试者餐后血糖水平，与体重变化无关 [<xref ref-type="bibr" rid="hanspub.41051-ref32">32</xref>]。因此，服用稳定的Ghrelin类似物是实现血糖控制的另一个潜在途径，尽管需要了解Ghrelin如何调节其对葡萄糖的影响。</p></sec><sec id="s10"><title>6. 研究展望</title><p>尽管在理想的代谢环境中，Ghrelin并不是葡萄糖稳态的主要参与者，但在代谢和营养的极端环境中，Ghrelin成为血糖控制的先锋。Ghrelin的葡萄糖调节作用可能是在极端负能量平衡(如饥饿)期间作为一个调节血糖的主要分子，在此期间，其血浆的葡萄糖水平自然升高。所以，我们认为靶向Ghrelin系统仍然是糖尿病患者血糖控制的可行机制。值得进一步研究。</p></sec><sec id="s11"><title>文章引用</title><p>陈 晶,赵冬静,王颜刚. 饥饿素在糖代谢中的作用以及在糖尿病中的研究综述Review on the Role of Ghrelin in Glucose Metabolism and Diabetes Mellitus[J]. 临床医学进展, 2021, 11(03): 1147-1153. https://doi.org/10.12677/ACM.2021.113165</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41051-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yanagi, S., Sato, T., Kangawa, K. and Nakazato, M. (2018) The Homeostatic Force of Ghrelin. Cell Metabolism, 27, 786-804. &lt;br&gt;https://doi.org/10.1016/j.cmet.2018.02.008</mixed-citation></ref><ref id="hanspub.41051-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Poher, A.L., Tschöp, M.H. and Müller, T.D. (2018) Ghrelin Regulation of Glucose Metabolism. Peptides, 100, 236-242. &lt;br&gt;https://doi.org/10.1016/j.peptides.2017.12.015</mixed-citation></ref><ref id="hanspub.41051-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pradhan, G., Samson, S.L. and Sun, Y. (2013) Ghrelin: Much More than a Hunger Hormone. Current Opinion in Clinical Nutrition and Metabolic Care, 16, 619-624. &lt;br&gt;https://doi.org/10.1097/MCO.0b013e328365b9be</mixed-citation></ref><ref id="hanspub.41051-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Mani, B.K. and Zigman, J.M. (2017) Ghrelin as a Survival Hormone. Trends in Endocrinology &amp; Metabolism, 28, 843-854. &lt;br&gt;https://doi.org/10.1016/j.tem.2017.10.001</mixed-citation></ref><ref id="hanspub.41051-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Muhammad, H.F.L. (2018) Obesity as the Sequel of Childhood Stunting: Ghrelin and GHSR Gene Polymorphism Explained. Acta Medica Indonesiana, 50, 159-164.</mixed-citation></ref><ref id="hanspub.41051-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lin, T.C. and Hsiao, M. (2017) Ghrelin and Cancer Progression. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1868, 51-57. &lt;br&gt;https://doi.org/10.1016/j.bbcan.2017.02.002</mixed-citation></ref><ref id="hanspub.41051-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Lv, Y., Liang, T., Wang, G. and Li, Z. (2018) Ghrelin, a Gastrointestinal Hormone, Regulates Energy Balance and Lipid Metabolism. Bioscience Reports, 38, Article ID: BSR20181061. &lt;br&gt;https://doi.org/10.1042/BSR20181061</mixed-citation></ref><ref id="hanspub.41051-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Cui, H., López, M. and Rahmouni, K. (2017) The Cellular and Molecular Bases of Leptin and Ghrelin Resistance in Obesity. Nature Reviews Endocrinology, 13, 338-351. &lt;br&gt;https://doi.org/10.1038/nrendo.2016.222</mixed-citation></ref><ref id="hanspub.41051-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kimber-Trojnar, Ż., Patro-Małysza, J., Skórzyńska-Dziduszko, K.E., Oleszczuk, J., Trojnar, M., Mierzyński, R., et al. (2018) Ghrelin in Serum and Urine of Post-Partum Women with Gestational Diabetes Mellitus. International Journal of Molecular Sciences, 19, 3001. &lt;br&gt;https://doi.org/10.3390/ijms19103001</mixed-citation></ref><ref id="hanspub.41051-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Brink, H.S., van der Lely, A.J., Delhanty, P.J.D., Huisman, M. and van der Linden, J. (2019) Gestational Diabetes Mellitus and the Ghrelin System. Diabetes &amp; Metabolism, 45, 393-395. &lt;br&gt;https://doi.org/10.1016/j.diabet.2017.10.013</mixed-citation></ref><ref id="hanspub.41051-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Napolitano, T., Silvano, S., Vieira, A., Garrido-Utrilla, A., Friano, M.E., Atlija, J. and Collombat, P. (2018) Role of Ghrelin in Pancreatic Development and Function. Diabetes, Obesity and Metabolism, 20, 3-10.  
&lt;br&gt;https://doi.org/10.1111/dom.13385</mixed-citation></ref><ref id="hanspub.41051-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sirchak, E.S. and Patskun, S.V. (2018) Interrelation between Ghrelin and Gastrin in Patients with Combination of Chronic Gastritis and Type 2 Diabetes mellitus. Wiadomości Lekarskie, 71, 311-314.</mixed-citation></ref><ref id="hanspub.41051-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kalinowski, P., Paluszkiewicz, R., Wróblewski, T., Remiszewski, P., Grodzicki, M., Bartoszewicz, Z., et al. (2017) Ghrelin, Leptin, and Glycemic Control after Sleeve Gastrectomy versus Roux-en-Y Gastric Bypass-Results of a Randomized Clinical Trial. Surgery for Obesity and Related Diseases, 13, 181-188.  
&lt;br&gt;https://doi.org/10.1016/j.soard.2016.08.025</mixed-citation></ref><ref id="hanspub.41051-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Abu Dayyeh, B.K., Jirapinyo, P. and Thompson, C.C. (2017) Plasma Ghrelin Levels and Weight Regain After Roux-en-Y Gastric Bypass Surgery. Obesity Surgery, 27, 1031-1036. &lt;br&gt;https://doi.org/10.1007/s11695-016-2418-3</mixed-citation></ref><ref id="hanspub.41051-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Xu, H.C., Pang, Y.C., Chen, J.W., Cao, J.-Y., Sheng, Z., Yuan, J.-H., et al. (2019) Systematic Review and Meta-Analysis of the Change in Ghrelin Levels After Roux-en-Y Gastric Bypass. Obesity Surgery, 29, 1343-1351. 
&lt;br&gt;https://doi.org/10.1007/s11695-018-03686-3</mixed-citation></ref><ref id="hanspub.41051-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Tamboli, R.A., Antoun, J., Sidani, R.M., Clements, A., Harmata, E.E., Marks-Shulman, P., et al. (2017) Metabolic Responses to Exogenous Ghrelin in Obesity and Early after Roux-en-Y Gastric Bypass in Humans. Diabetes, Obesity and Metabolism, 19, 1267-1275. &lt;br&gt;https://doi.org/10.1111/dom.12952</mixed-citation></ref><ref id="hanspub.41051-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Steinert, R.E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C. and Geary, N. (2017) Ghrelin, C.C.K. GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. Physiological Reviews, 97, 411-463. &lt;br&gt;https://doi.org/10.1152/physrev.00031.2014</mixed-citation></ref><ref id="hanspub.41051-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Song, X., Jiao, H., Zhao, J., Wang, X. and Lin, H. (2018) Dexamethasone and Insulin Stimulate Ghrelin Secretion of Broilers in a Different Way. General and Comparative Endocrinology, 268, 14-21.  
&lt;br&gt;https://doi.org/10.1016/j.ygcen.2018.07.009</mixed-citation></ref><ref id="hanspub.41051-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Yu, X., Rong, S.S., Sun, X., Ding, G.F., Wan, W.L., Zou, L.Y., et al. (2018) Associations of Breast Milk Adiponectin, Leptin, Insulin and Ghrelin with Maternal Characteristics and Early Infant Growth: A Longitudinal Study. British Journal of Nutrition, 120, 1380-1387. &lt;br&gt;https://doi.org/10.1017/S0007114518002933</mixed-citation></ref><ref id="hanspub.41051-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ma, X., Lin, L., Yue, J., Wu, C.-S., Guo, C.A., Wang, R., et al. (2017) Suppression of Ghrelin Exacerbates HFCS-Induced Adiposity and Insulin Resistance. International Journal of Molecular Sciences, 18, 1302. 
&lt;br&gt;https://doi.org/10.3390/ijms18061302</mixed-citation></ref><ref id="hanspub.41051-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Y., Liang, Z., He, L., Yang, M.L., Liu, D.F., Gu, H.F., et al. (2019) Gut Ghrelin Regulates Hepatic Glucose Production and Insulin Signaling via a Gut-Brain-Liver Pathway. Cell Communication and Signaling, 17, Article No. 8.  
&lt;br&gt;https://doi.org/10.1186/s12964-019-0321-y</mixed-citation></ref><ref id="hanspub.41051-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Jandaghi, P., Hoheisel, J.D. and Riazalhosseini, Y. (2015) GHSR Hypermethylation: A Promising Pan-Cancer Marker. Cell Cycle, 14, 689-690.</mixed-citation></ref><ref id="hanspub.41051-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Lou, J., Liu, L., Zhang, W., Zhou, Z. and Fan, Y. (2019) Differential Expression of Ghrelin and GHSR via the mTOR Pathway during the Dynamic Carcinogenic Process Involving Oral, Potentially Malignant Disorders. Bioscience Reports, 39, Article ID: BSR20192102. &lt;br&gt;https://doi.org/10.1080/15384101.2015.1006051</mixed-citation></ref><ref id="hanspub.41051-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, M.J. and Wang, T. (2020) The New Mechanism of Ghrelin/GHSR-1a on Autophagy Regulation. Peptides, 126, Article ID: 170264. &lt;br&gt;https://doi.org/10.1016/j.peptides.2020.170264</mixed-citation></ref><ref id="hanspub.41051-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ye, H., Yang, Y., Chen, R., Shi, X., Fang, Y., Yang, J., et al. (2019) Recognition of Invasive Prostate Cancer Using a GHRL Polypeptide Probe Targeting GHSR in a Mouse Model in Vivo. Current Pharmaceutical Design, 26, 1614-1621.  
&lt;br&gt;https://doi.org/10.2174/1381612826666191227160001</mixed-citation></ref><ref id="hanspub.41051-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Davis, J. (2018) Hunger, Ghrelin and the Gut. Brain Research, 1693, 154-158.  
&lt;br&gt;https://doi.org/10.1016/j.brainres.2018.01.024</mixed-citation></ref><ref id="hanspub.41051-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Thomas, M.A., Ryu, V. and Bartness, T.J. (2016) Central Ghrelin Increases Food Foraging/Hoarding That Is Blocked by GHSR Antagonism and Attenuates Hypothalamic Paraventricular Nucleus Neuronal Activation. American Journal of Physiology, 310, R275-R285. &lt;br&gt;https://doi.org/10.1152/ajpregu.00216.2015</mixed-citation></ref><ref id="hanspub.41051-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, K., Zhang, M.L., Liu, S.T., Li, X.-Y., Zhong, S.M., Li, F., et al. (2017) Ghrelin Attenuates Retinal Neuronal Autophagy and Apoptosis in an Experimental Rat Glaucoma Model. Investigative Ophthalmology &amp; Visual Science, 58, 6113-6122. &lt;br&gt;https://doi.org/10.1167/iovs.17-22465</mixed-citation></ref><ref id="hanspub.41051-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Han, Q.Q., Huang, H.J., Wang, Y.L., Yang, L., Pilot, A., Zhu, X.-C., et al. (2019) Ghrelin Exhibited Antidepressant and Anxiolytic Effect via the p38-MAPK Signaling Pathway in Hippocampus. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 93, 11-20. &lt;br&gt;https://doi.org/10.1016/j.pnpbp.2019.02.013</mixed-citation></ref><ref id="hanspub.41051-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Fuente-Martín, E., García-Cáceres, C., Argente-Arizón, P., Díaz, F., Granado, M., Freire-Regatillo, A., et al. (2016) Ghrelin Regulates Glucose and Glutamate Transporters in Hypothalamic Astrocytes. Scientific Reports, 6, Article No. 23673. &lt;br&gt;https://doi.org/10.1038/srep23673</mixed-citation></ref><ref id="hanspub.41051-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Wallace Fitzsimons, S.E., Chruścicka, B., Druelle, C., Stamou, P., Nally, K., Dinan, T.G., et al. (2019) A Ghrelin Receptor and Oxytocin Receptor Heterocomplex Impairs Oxytocin Mediated Signalling. Neuropharmacology, 152, 90-101. &lt;br&gt;https://doi.org/10.1016/j.neuropharm.2018.12.022</mixed-citation></ref><ref id="hanspub.41051-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Hsu, T.M., Suarez, A.N. and Kanoski, S.E. (2016) Ghrelin: A Link between Memory and Ingestive Behavior. Physiology &amp; Behavior, 162, 10-17. &lt;br&gt;https://doi.org/10.1016/j.physbeh.2016.03.039</mixed-citation></ref></ref-list></back></article>